Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Eli Lilly and Company (LLY) announced that international president Patrik Jonsson will retire at the end of 2026 after 36 years.
Effective Jan. 1, 2027, Lilly will combine its U.S. and international businesses into Lilly Global Markets. Ilya Yuffa will become executive vice president and president of the organization, overseeing customer strategy and execution worldwide. Lilly expects the consolidation to accelerate decision-making and increase scalability.
Laura Steele will be promoted to president, Lilly USA, and Elias Khalil to group vice president and president, Lilly Europe and Canada. They will join the leaders of the other four geographic hubs in reporting to Yuffa.
Eli Lilly (LLY) declared a fourth-quarter 2026 dividend of $1.73 per share on its outstanding common stock. The dividend is payable on December 10, 2026, to shareholders of record at the close of business on November 13, 2026.
Eli Lilly and Company (NYSE: LLY) presented updated olomorasib combination results for first-line KRAS G12C-mutant non-small cell lung cancer at ESMO 2026.
Among 85 patients receiving olomorasib plus pembrolizumab without chemotherapy, median response duration and progression-free survival, the time without disease worsening, were not reached after median follow-up of 20.7 months. In a separate single-arm analysis of 77 patients receiving olomorasib plus pembrolizumab and chemotherapy, the investigator-assessed confirmed response rate was 62%, median response duration was 14.5 months and median progression-free survival was 11.6 months. Treatment-related adverse events led to regimen discontinuation in 11.8% and 7.8%, respectively; neither group had fatal treatment-related events. Lilly expects the first randomized Phase 3 SUNRAY-01 results in the first half of 2027. Part B has completed enrollment.
Eli Lilly and Company (NYSE: LLY) reported a 79% confirmed response rate for investigational Sofe-M plus bevacizumab in platinum-sensitive ovarian cancer.
The Phase 1 cohort included 33 women; efficacy results covered 29 with measurable disease at the July 6, 2026 cutoff. Disease control was 100%, with six complete and 17 partial responses. Activity was consistent across folate receptor alpha expression levels and prior PARP inhibitor exposure. Median response duration and progression-free survival were not reached at median follow-ups of 6.2 and 10.2 months, respectively.
Grade 3 or higher neutropenia occurred in 42% and anemia in 24%; dose reductions occurred in 42%, and 6% discontinued because of adverse events. No new safety signals were observed. Lilly is evaluating Sofe-M in the Phase 3 FRAmework-01 program across platinum-sensitive and platinum-resistant ovarian cancer.
Eli Lilly and Company (LLY) broke ground on a $5 billion manufacturing facility in Goochland County, just west of Richmond, Virginia. The site will be Lilly's first integrated facility producing both active pharmaceutical ingredients, the components that make medicines work, and finished medicines. It will manufacture antibody-drug conjugates, targeted cancer treatments.
The project is part of Lilly's more than $50 billion U.S. production expansion, encompassing 10 sites announced since 2020. Lilly expects the Richmond facility to create 650 high-wage jobs and approximately 1,800 construction jobs. It has also committed $40 million to a Virginia pharmaceutical manufacturing training network, including a hands-on center targeted to open in 2028.
Eli Lilly (NYSE: LLY) reported that Omvoh met the primary endpoint in its Phase 3 pediatric ulcerative colitis study. In SHINE-2, 81% achieved clinical response at Week 12. Among 52 responders ages 6 to 17, 50% achieved clinical remission at Week 52. The single-arm, open-label study used a benchmark derived from an adult placebo group, not a concurrent control group.
Among responders at Week 52, 71.2% achieved symptomatic remission and 50% achieved corticosteroid-free clinical remission without surgery. Endoscopic improvement was 53.8%, and endoscopic remission was 44.2%. Through Week 52, four patients (6.3%) had serious adverse events, none considered treatment-related; two (3.2%) discontinued because of ulcerative colitis flare. No new safety signals were identified. Lilly plans global regulatory submissions to support a potential pediatric label expansion; Omvoh is currently approved for adults.
Eli Lilly (NYSE: LLY) will present oncology research at the European Society for Medical Oncology Congress, October 23–27 in Madrid, Spain.
Presentations include first Phase 1 data for sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and updated olomorasib combination data in previously untreated, advanced lung cancer with a KRAS G12C mutation. Both investigational therapies have ongoing Phase 3 trials. Lilly will also present updated Phase 3 LIBRETTO-531 results comparing selpercatinib with cabozantinib or vandetanib in advanced, RET-mutant medullary thyroid cancer not previously treated with a kinase inhibitor. A separate presentation covers overall survival from Phase 3 postMONARCH, testing abemaciclib plus fulvestrant in HR-positive, HER2-negative advanced breast cancer after progression on a prior CDK4/6 inhibitor and endocrine therapy.
Eli Lilly and Company (LLY) will announce its third-quarter 2026 financial results on October 29, 2026. A conference call for investors and media will begin that day at 10 a.m. Eastern time. A live webcast and a subsequent replay will be available on Lilly's investor website.
Eli Lilly (LLY) reported new Omvoh analyses showing corticosteroid-free composite disease control in ulcerative colitis and deep remission in Crohn's disease.
The post hoc analyses, conducted after the original trials, assessed outcomes at one year. In LUCENT-2, 27.7% of Omvoh-treated ulcerative colitis patients achieved comprehensive disease control versus 14% receiving placebo. This combined symptom, endoscopic and tissue remission, an inflammation marker threshold and no corticosteroid use. Patients had first responded to Omvoh during induction. In VIVID-1, 20.4% achieved corticosteroid-free deep remission versus 2% receiving placebo, combining clinical and endoscopic remission with no corticosteroid use. Both endpoints required no corticosteroids for at least 12 weeks before Week 52. Benefits were also observed after prior biologic treatment failure; endpoint achievement was associated with better patient-reported quality of life.
Eli Lilly and Company (LLY) announced exploratory Phase 3b results comparing combined Taltz and Zepbound treatment with Taltz alone in psoriasis.
The TOGETHER-PsO analysis covered adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related condition. Broader changes in biomarkers—measurable biological indicators—appeared with combined treatment as early as Week 12. By Week 36, changes involved 482 versus 140 proteins and 467 versus 16 genes. Combined treatment also showed greater reductions in inflammatory immune activity.
Previously reported results showed superior skin clearance and clinically meaningful weight reduction versus Taltz alone at Week 36, with improvements maintained or further improved through Week 52. Safety was consistent with each medicine's known profile. The randomized study enrolled 274 participants.